Shinji Nakamichi

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026

Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.

Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study.

Journal: JTO clinical and research reports
Published: February 12, 2026

Prognostic impact of thyroid transcription factor-1 expression and the efficacy of carboplatin plus (nab-) paclitaxel in non-squamous non-small cell lung cancer complicated with idiopathic interstitial pneumonias.

Prognostic impact of thyroid transcription factor-1 expression and the efficacy of carboplatin plus (nab-) paclitaxel in non-squamous non-small cell lung cancer complicated with idiopathic interstitial pneumonias.

Journal: Translational lung cancer research
Published: November 28, 2025

SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer.

SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer.

Journal: Carcinogenesis
Published: September 30, 2025

Retrospective study on the tolerability using a four-cycle completion in elderly patients with extensive-stage small-cell lung cancer: a body mass index-based analysis.

Retrospective study on the tolerability using a four-cycle completion in elderly patients with extensive-stage small-cell lung cancer: a body mass index-based analysis.

Journal: Translational lung cancer research
Published: September 12, 2025

SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer.

SRSF3 knockdown-induced cellular senescence as a possible therapeutic strategy for non-small cell lung cancer.

Journal: bioRxiv : the preprint server for biology
Published: June 26, 2025

The senescence-inhibitory p53 isoform Δ133p53α: enhancing cancer immunotherapy and exploring novel therapeutic approaches for senescence-associated diseases.

The senescence-inhibitory p53 isoform Δ133p53α: enhancing cancer immunotherapy and exploring novel therapeutic approaches for senescence-associated diseases.

Journal: GeroScience
Published: June 05, 2025

Phase II Study of Short Hydration without Diuretics for Cisplatin-Based Chemotherapy.

Phase II Study of Short Hydration without Diuretics for Cisplatin-Based Chemotherapy.

Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
Published: May 21, 2025

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 13, 2024

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).

Journal: Targeted oncology
Published: March 04, 2024

Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.

Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.

Journal: Cancer science
Published: November 29, 2023

Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.

Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.

Journal: Cancer medicine
Published: October 11, 2023
Showing 1-12 of 50

Last Updated: 09/26/2026